Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow7.39 M USD-6.14 M USD3.97 M USD6.50 M USD-1.68 M USD2.90 M USD1.86 M USD-1.23 M USD-2.84 M USD-6.45 M USD-9.63 M USD-3.43 M USD
Depreciation & Amortization1.60 M USD1.70 M USD2.10 M USD1.50 M USD1.20 M USD825000 USD606000 USD360000 USD168000 USD156000 USD214000 USD213000 USD
Stock-Based Compensation654000 USD1.12 M USD864000 USD912000 USD598000 USD600000 USD636000 USD1.00 M USD2.66 M USD2.60 M USD3.16 M USD2.81 M USD
Capital Expenditures389000 USD836000 USD2.87 M USD2.38 M USD3.28 M USD2.22 M USD834000 USD1.23 M USD766000 USD322000 USD119000 USD234000 USD
Cash Flow from Investing-389000 USD-836000 USD-2.87 M USD-2.38 M USD-3.17 M USD-2.22 M USD-834000 USD-1.23 M USD-766000 USD-322000 USD-114000 USD-234000 USD
Cash Flow from Financing170000 USD-527000 USD11000 USD207000 USD1.20 M USD4.42 M USD1.20 M USD13000 USD4.32 M USD2000 USD13.21 M USD21000 USD
Dividends Paid
Stock Buybacks0 USD634000 USD74000 USD0 USD
Free Cash Flow7.00 M USD-6.97 M USD1.10 M USD4.11 M USD-4.96 M USD685000 USD1.03 M USD-2.46 M USD-3.61 M USD-6.77 M USD-9.75 M USD-3.67 M USD

Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.